Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 3/20 | 0.43 |
| ▸ | SCD | O00767 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232610 | 0.85 | PTGDR2 (0.51) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL7095938 | 0.81 | PTGDR2 (0.47) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL8822065 | 0.80 | PTGDR2 (0.46) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL4018735 | 0.80 | PTGDR2 (0.45) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL6095719 | 0.78 | MGLL (0.53) | PTGDR2POLBMGLLTP53MAPT | |
| SCHEMBL7840752 | 0.77 | POLB (0.54) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL7082509 | 0.77 | PTGDR2 (0.52) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL7839750 | 0.77 | MGLL (0.54) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL7841588 | 0.76 | POLB (0.54) | PTGDR2POLBMGLLSCDTP53 | |
| SCHEMBL7830249 | 0.76 | MGLL (0.52) | PTGDR2POLBMGLLSCDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | PTGDR2 1837/4885POLB 652/4885MGLL 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.